Ron H. N. van Schaik
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
BACKGROUND: A genotype-guided de-escalation strategy—switching from a potent P2Y 12 inhibitor to clopidogrel—may reduce bleeding risk in patients with acute coronary syndrome (ACS). This analysis evaluated the safety and effectiveness of routine genetic testing to guide antiplatelet therapy in clinical practice. METHODS: In this investigator-initiated, prospective, multicenter implementation study, patients received either standard care, with antiplatelet therapy at the physician discretion, or genotype-guided therapy. In the genotype-guided group, physicians were recommended to switch to clopidogrel in noncarriers of CYP2C19 loss-of-function alleles. The coprimary end points were major adverse cardiac events, a composite of cardiovascular death, myocardial infarction, or stroke, and major or nonmajor clinically relevant bleeding, at 1 year of follow-up. Hazard ratios were adjusted for baseline differences between cohorts using multivariable Cox regression. Net adverse cardiac events comprised all-cause death, myocardial infarction, stroke, stent thrombosis, and major bleeding. A Bonferroni-adjusted significance level of α =0.025 was applied. RESULTS: A total of 9907 patients were included in the analysis. Of these, 1208 (12%) were included in the genotype-guided cohort, whereas 8699 (88%) were assigned to the standard care cohort. Major adverse cardiac events occurred in 107 patients (8.9%) in the genotype-guided cohort and 897 patients (10.3%) in the standard care cohort (adjusted hazard ratio, 1.05 [95% CI, 0.85–1.29]; P =0.64). Major or nonmajor clinically relevant bleeding was reported in 146 patients (12.1%) in the genotype-guided cohort compared with 1384 patients (15.9%) in the standard care cohort (adjusted hazard ratio, 0.79 [95% CI, 0.67–0.94]; P =0.01). There was no significant association with net adverse cardiac events (adjusted hazard ratio, 0.91 [95% CI, 0.76–1.09]; P =0.31). CONCLUSIONS: In patients with acute coronary syndrome receiving antiplatelet therapy, implementation of a CYP2C19 genotype-guided de-escalation strategy in clinical practice was associated with a significant reduction of major and nonmajor clinically relevant bleeding compared with standard care at 12 months, without increasing ischemic events. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03823547.
Year:
2026
Background and Aims A genotype-guided de-escalation strategy - switching from a potent P2Y12-inhibitor to clopidogrel - may represent an effective and safe approach to reducing bleeding risk in patients with acute coronary syndrome (ACS). This analysis aimed to evaluate the safety and effectiveness of routine genetic testing to guide antiplatelet therapy in clinical practice. Methods In this investigator-initiated, prospective, multicentre implementation study, patients were divided into a standard care cohort, where antiplatelet therapy was prescribed at the physician’s discretion (with a potent P2Y12 inhibitor as the default choice), and a genotype-guided cohort. In the genotype-guided group, physicians were recommended to switch to clopidogrel in noncarriers of CYP2C19 loss-of-function alleles during hospital admission. The primary endpoints were major adverse cardiac events (MACE), defined as a composite of cardiovascular death, myocardial infarction, or stroke, and major or non-major clinically relevant bleeding (Bleeding Academic Research Consortium types 2, 3, or 5), at one year of follow-up. Hazard ratios were adjusted for baseline differences between cohorts using multivariable Cox regression. Results A total of 9,907 patients were included in the analysis. Of these, 1,208 (12%) were included in the genotype-guided cohort, while 8,699 (88%) were assigned to the standard care cohort. MACE occurred in 107 patients (8.9%) in the genotype-guided cohort and 897 patients (10.3%) in the standard care cohort ( adj HR 1.05; 95% CI 0.85-1.29; P = 0.64). Major or non-major clinically relevant bleeding was reported in 146 patients (12.1%) in the genotype-guided cohort compared to 1,384 patients (15.9%) in the standard care cohort ( adj HR 0.79; 95% CI 0.67–0.94; P = 0.01). Conclusion In patients with ACS receiving antiplatelet therapy, implementation of a CYP2C19 genotype-guided de-escalation strategy in clinical practice significantly reduced major and non-major clinically relevant bleeding compared to standard care at 12 months, without increasing ischemic events.
Year:
2025
Aims To enhance understanding of betamethasone and its metabolites' pharmacokinetics in pregnancy, specifically early‐onset pre‐eclampsia, through a population pharmacokinetic model. Additionally, to investigate the placental metabolism and transfer of betamethasone and its main metabolites. Methods A prospective, single‐centre pharmacokinetic study was conducted in pregnant women ( n = 28) with imminent preterm birth treated with intramuscular betamethasone. Betamethasone serum concentrations were determined from serial venous blood samples ( n = 194). Placental transfer and metabolism were studied using ex vivo human placental perfusion (healthy term; n = 3) and placental explant experiments (healthy term, n = 4; early‐onset pre‐eclampsia, n = 4). Additionally, placental mRNA expression of CYP3A4, CYP3A7, 11β‐hydroxysteroid dehydrogenase (HSD) 1 and 11β‐HSD2 were quantified in healthy and early‐onset pre‐eclampsia placentas. Results The population pharmacokinetic model was best described by a 2‐compartment nonlinear mixed effects model. Betamethasone clearance in early‐onset pre‐eclamptic women was 60% lower of that observed in women without pre‐eclampsia (9.35 vs . 15.78 L/h), resulting in a 40% median increase in maternal betamethasone exposure (1567 vs . 1114 ng h/mL). Ex vivo experiments showed placental transfer of betamethasone to the foetal circulation (foetal‐to‐maternal ratio 0.76 ± 0.05 [in a perfused placental cotyledon]). The placenta only converted betamethasone into 11‐ketobetamethasone, with similar ratios in early‐onset pre‐eclampsia and healthy placental explants (3.0 ± 2.2 vs . 1.4 ± 0.4 per mg tissue, P = .27). The expression of 11β‐HSD1 mRNA was lower in early‐onset pre‐eclampsia placentas ( P = .015), while placental CYP3A7 and 11β‐HSD2 mRNA expression were similar. Conclusion Women with early‐onset pre‐eclampsia have elevated betamethasone exposure. Betamethasone transfers freely into the foetal circulation, with placental metabolism resulting only in 11‐ketobetamethasone. Decreased placental 11β‐HSD1 expression may play a role in increased betamethasone exposure in early‐onset pre‐eclampsia.
Year:
2025
Pharmacogenetic studies involving Carboxylesterase 1 (CES1), Latrophilin‐3 (LPHN3), and Catechol‐O‐methyltransferase (COMT) revealed individual differences regarding therapeutic response in children with attention deficit hyperactivity disorder (ADHD) under methylphenidate (MPH) treatment. This study aimed to evaluate MPH's association with the adverse effect status in children and its relationship with CES1, LPHN3, and COMT in the Turkish population. The study included 102 children and adolescents with ADHD, who were categorized as responders, or the adverse effect group based on their treatment response. The Naranjo Adverse Drug Reaction Probability Scale evaluated the presence and severity of adverse effects. Saliva sample was taken from the patients and genotype distribution of CES1 rs3815583, CES1 rs2307227, LPHN3 rs6551665, LPHN3 rs1947274, LPHN3 rs6858066, LPHN3 rs2345039, and COMT rs4680 were examined. In the adverse effect group, instances of carrying the GG genotype in CES1 rs2307227, having G vs. T genotype and GG vs. GT were significantly higher. In LPHN3 rs2345039, carrying the C genotype vs. G was associated with a serious adverse effect. In COMT rs4680, individuals with the AA or GG genotype were significantly higher in the adverse effect group. Our study suggests a relationship between genetic polymorphisms and the side effect status in children receiving MPH.
Year:
2025
Neutropenia is the major dose‐limiting toxicity of irinotecan‐based therapy. The objective of this study was to assess whether inclusion of germline genetic variants into a population pharmacokinetic/pharmacodynamic model can improve prediction of irinotecan‐induced grade 4 neutropenia and identify novel variants of clinical value. A semimechanistic population pharmacokinetic/pharmacodynamic model was used to predict neutrophil response over time in 197 patients receiving irinotecan. Covariate analysis was performed for demographic/clinical factors and 4,781 genetic variants in 84 drug response‐ and toxicity‐related genes to identify covariates associated with neutrophil response. We evaluated the predictive value of the model for grade 4 neutropenia reflecting different clinical scenarios of available data on identified demographic/clinical covariates, baseline and post‐treatment absolute neutrophil counts (ANCs), individual pharmacokinetics, and germline genetic variation. Adding 8 genetic identified covariates (rs10929302 ( UGT1A1 ), rs1042482 ( DPYD ), rs2859101 ( HLA‐DQB3 ), rs61754806 ( NR3C1 ), rs9266271 ( HLA‐B ), rs7294 ( VKORC1 ), rs1051713 ( ALOX5 ), and ABCB1 rare variant burden) to a model using only baseline ANCs improved prediction of irinotecan‐induced grade 4 neutropenia from area under the receiver operating characteristic curve (AUC‐ROC) of 50–64% (95% confidence interval (CI), 54–74%). Individual pharmacokinetics further improved the prediction to 74% (95% CI, 64–84%). When weekly ANC was available, the identified covariates and individual pharmacokinetics yielded no additional contribution to the prediction. The model including only ANCs at baseline and at week 1 achieved an AUC‐ROC of 78% (95% CI, 69–88%). Germline DNA genetic variants may contribute to the prediction of irinotecan‐induced grade 4 neutropenia when incorporated into a population pharmacokinetic/pharmacodynamic model. This approach is generalizable to drugs that induce neutropenia and ultimately allows for personalized intervention to enhance patient safety.
Year:
2024
PURPOSE Around 20%-30% of patients treated with fluoropyrimidines develop severe treatment-related adverse events (AEs). These are mainly caused by deficiency of dihydropyrimidine dehydrogenase, its main metabolizing enzyme. The DPYD*7 variant allele contains a frameshift mutation that leads to absence of dihydropyrimidine dehydrogenase. Clinical studies on this variant in patients treated with fluoropyrimidines are lacking because of its low minor allelic frequency. However, the DPYD*7 minor allelic frequency is 56-times higher in the Dutch compared with the global population. This allowed us to evaluate fluoropyrimidine tolerability in DPYD*7 variant allele carriers. MATERIALS AND METHODS Patients treated with standard-of-care fluoropyrimidine who were pretreatment DPYD genotyped for DPYD*2A, *13, 2846A>T, and 1236G>A single-nucleotide polymorphisms were included for analyses. Patients were additionally screened for the DPYD*7 allele (rs72549309, 295-298delTCAT). AEs were graded if they worsened from baseline, according to Common Terminology Criteria for Adverse Events version 5.0. AEs ≥ grade 3 were considered severe. RESULTS From 3,748 patients, we found 13 patients carrying heterozygous DPYD*7. Relevant clinical data were available for 11 patients. All patients developed fluoropyrimidine-related AEs, of which five patients developed severe AEs (46%). From these five patients, three patients were started with 65% or 50% of standard dose, but apparently still developed severe toxicity. Because of severe AEs, three patients discontinued treatment prematurely (one patient already started with 50% of standard dose) and one patient who started with 50% of standard dose was further reduced to 35% of standard dose. CONCLUSION In this study, the clinical consequences of carrying the DPYD*7 variant allele were confirmed as 46% of the patients developed severe AEs, even in the presence of initial dose reductions. This underlines the need for prospective studies investigating the required fluoropyrimidine dose for DPYD*7 carriers.
Year:
2022
Collaborators (9)
karel allegaert
Researcher
Erasmus University Rotterdam
Robert Bies
Professor
State University of New York at Buffalo
Philip L. J. DeKoninck
-
Jose PS Henriques
Prof.dr
Academic Medical Center
Ron Mathijssen
Full professor
Erasmus University Rotterdam
A. H. Jan Danser
Professor of Pharmacology
Erasmus MC
Sinno Simons
Erasmus MC
Yolande Appelman
VU medisch centrum
Federico Innocenti
University of North Carolina at Chapel Hill
Make your next move.
Prepare your application
Review drafts before you send them.